Thermo Fisher Scientific has expanded its biologics manufacturing capabilities with the opening of a modern facility in Lengnau, Switzerland. The site will focus on the production of biologics, a rapidly growing segment of the pharmaceutical industry, according to a company announcement.
The Lengnau facility represents a significant investment by Thermo Fisher Scientific in its biomanufacturing network. The company stated the new site will enhance its ability to support pharmaceutical and biotech companies in bringing new therapies to market. The facility’s capabilities include cell culture, purification and fill-finish operations.
The expansion comes as demand for biologics continues to increase globally. Biologics, which are derived from living organisms, are often used to treat complex diseases such as cancer, autoimmune disorders, and infectious diseases. Thermo Fisher Scientific’s investment aims to address the growing need for large-scale, high-quality biologics manufacturing capacity.
Pharmaceutical Technology reported on the opening of the Lengnau facility, highlighting its role in supporting the development and production of innovative therapies. The company did not disclose the specific financial details of the investment, but emphasized its commitment to the Swiss biopharmaceutical ecosystem.
Alongside the expansion of manufacturing capacity, research continues in related fields. A recent study published in Nature details a microfluidic platform for co-culturing microtissues with continuously recirculating suspension cells, potentially advancing drug discovery and personalized medicine. Another Nature publication explores FcRn-silencing of IL-12Fc to prevent toxicity in glioblastoma therapy, demonstrating ongoing innovation in targeted drug delivery.
Thermo Fisher Scientific has not yet announced specific production timelines or client engagements for the Lengnau facility. The company’s website lists job openings for roles including “Mitarbeiter Etikettenandrucke/ Text Layouter” at the Allschwil location, indicating ongoing staffing efforts to support the expanded operations.
